文献速递基础与转化研究新药、器械与细胞基因治疗研发

异源序贯加强免疫在人源化小鼠中驱动HIV广谱中和抗体前体早期成熟

Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice.
PubMed 文献 · Sci Transl Med · 2024-05-22

研究设计core-g28v2 60mer纳米颗粒免疫原,用于eOD-GT8 60mer初免后的首次加强。在人源化小鼠模型中,蛋白和mRNA异源序贯加强方案均诱导出获得关键突变、结合缺失N276聚糖的近天然HIV包膜三聚体的VRC01类抗体,mRNA方案诱导的抗体可中和缺失N276聚糖的假病毒,支持启动IAVI G002 1期试验。

要点

  • 蛋白和mRNA异源序贯加强均诱导VRC01类抗体获得关键突变并结合近天然包膜三聚体。
  • mRNA方案诱导的VRC01类抗体可中和缺失N276聚糖的假病毒。
  • 结果支持启动IAVI G002 1期试验测试mRNA编码纳米颗粒初免-加强方案。

核心结论

  • 异源加强免疫可驱动VRC01类广谱中和抗体前体向成熟方向发育,并支持启动IAVI G002 1期试验。

研究设计与样本

  • 在人源化小鼠模型中模拟人类VRC01类前体B细胞的多样性、亲和力和频率,评估蛋白和mRNA异源序贯加强方案。

主要发现

  • 蛋白和mRNA异源序贯加强方案均诱导VRC01类抗体获得关键突变并结合缺失N276聚糖的近天然HIV包膜三聚体。
  • mRNA方案诱导的VRC01类抗体可中和缺失N276聚糖的假病毒。

关键数值与推荐

  • IAVI G001 1期临床试验中,AS01B佐剂的eOD-GT8 60mer在97%的受种者中诱导VRC01类广谱中和抗体前体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A protective HIV vaccine will likely need to induce broadly neutralizing antibodies (bnAbs). Vaccination with the germline-targeting immunogen eOD-GT8 60mer adjuvanted with AS01B was found to induce VRC01-class bnAb precursors in 97% of vaccine recipients in the IAVI G001 phase 1 clinical trial; however, heterologous boost immunizations with antigens more similar to the native glycoprotein will be required to induce bnAbs. Therefore, we designed core-g28v2 60mer, a nanoparticle immunogen to be used as a first boost after eOD-GT8 60mer priming. We found, using a humanized mouse model approximating human conditions of VRC01-class precursor B cell diversity, affinity, and frequency, that both protein- and mRNA-based heterologous prime-boost regimens induced VRC01-class antibodies that gained key mutations and bound to near-native HIV envelope trimers lacking the N276 glycan. We further showed that VRC01-class antibodies induced by mRNA-based regimens could neutralize pseudoviruses lacking the N276 glycan. These results demonstrated that heterologous boosting can drive maturation toward VRC01-class bnAb development and supported the initiation of the IAVI G002 phase 1 trial testing mRNA-encoded nanoparticle prime-boost regimens.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Cottrell CA, Hu X, Lee JH, et al. Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice. Sci Transl Med. 2024. PMID: 38753806. doi:10.1126/scitranslmed.adn0223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。